JNJHealthcare · Drug Manufacturers - GeneralThe 23 Wall Street analysts covering Johnson & Johnson hold a median 12-month price target of $281 — +3.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 84 of 100 as at 27 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Johnson & Johnson on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (100): The share price has been relatively steady.
Revisions (45): Analysts have, on balance, been cutting their forecasts.
Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on JNJ, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +3.5% from it.
Of the 20 most recent actions, 8 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Oct 2026 | Wells Fargo | Maintains | Overweight | $275 → $287 |
| 15 Oct 2026 | Morgan Stanley | Maintains | Overweight | $294 → $292 |
| 14 Oct 2026 | Leerink Partners | Maintains | Outperform | $276 → $272 |
| 14 Oct 2026 | RBC Capital | Maintains | Outperform | $290 → $280 |
| 14 Oct 2026 | Wells Fargo | Maintains | Overweight | $282 → $275 |
| 7 Oct 2026 | Guggenheim | Reiterates | Buy | $287 |
| 7 Oct 2026 | Guggenheim | Reiterates | Buy | — |
| 6 Oct 2026 | RBC Capital | Maintains | Outperform | $287 → $290 |
| 6 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 5 Oct 2026 | Citigroup | Maintains | Buy | — |
| 5 Oct 2026 | Citigroup | Maintains | Buy | $298 → $303 |
| 29 Sept 2026 | JP Morgan | Maintains | Neutral | $270 → $285 |
| 29 Sept 2026 | JP Morgan | Maintains | Neutral | — |
| 10 Sept 2026 | HSBC | Maintains | Buy | — |
| 10 Sept 2026 | HSBC | Maintains | Buy | $290 → $320 |
| 2 Sept 2026 | UBS | Maintains | Buy | $280 → $320 |
| 2 Sept 2026 | UBS | Maintains | Buy | — |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 6 Aug 2026 | Guggenheim | Maintains | Buy | $270 → $287 |
| 3 Aug 2026 | Wells Fargo | Maintains | Overweight | $272 → $282 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
JNJ appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Johnson & Johnson returned +48.2% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 19% of US stocks
Cheaper than 12% of US stocks
Cheaper than 16% of US stocks
Higher than 42% of US stocks
Higher than 3% of US stocks
Higher than 81% of US stocks
Higher than 84% of US stocks
Higher than 79% of US stocks
Higher than 81% of US stocks
Higher than 89% of US stocks
Higher than 79% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Johnson & Johnson has a market value of $646.9B and an enterprise value of $674.3B.
Revenue in the twelve months to 30 June 2026: $97.9B. The latest quarter grew 5.9% year on year.
Net income over the same four quarters: $21.0B, a 21.5% net margin.
Diluted earnings per share, trailing twelve months: $8.63.
Free cash flow in the twelve months to 30 June 2026: $22.2B, after $5.4B of capital spending.
Johnson & Johnson spent $8.1B on share buybacks and $12.6B on dividends in the twelve months to 30 June 2026.
Trailing P/E: 40.8×; forward P/E: 23.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.97%, paying out 80% of earnings.
Johnson & Johnson employs 138,200 people — $709K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Johnson & Johnson — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The item says Medtronic’s 49-year dividend-raising streak is surpassed by two medical-device rivals. It points to differences in dividend yield, valuation, and balance-sheet strength among the companies.
Why it matters — Johnson & Johnson watchers may find the comparison relevant to its position among medical-device companies with long dividend-raising records.
Zacks Investment Research highlighted LLY, NVS, JNJ and ABBV as arthritis-drug stocks with growth potential, citing rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
Why it matters — JNJ is included among the companies whose arthritis-drug developments and sales are identified as relevant to monitor.
Johnson & Johnson will hold an Enterprise Business Review for the investment community on December 8, 2026. Company leaders plan to review its Innovative Medicine and MedTech businesses, pipelines, and long-term strategy.
Why it matters — The event will give JNJ watchers an opportunity to hear management discuss its businesses, pipeline priorities, and long-term strategy.
MarketBeat says that although the S&P 500 was recently just 2.5% below its all-time high, conditions look weaker beyond the index. Its headline describes five beaten-down growth stocks trading like value plays as cash moves toward mega-cap stocks.
Why it matters — The excerpt offers broader market context relevant to JNJ watchers but does not mention Johnson & Johnson specifically.
A 24/7 Wall Street headline highlights two S&P 500 dividend stocks as potentially suitable for long-term holding by retirees. The excerpt emphasizes dividends that continue and grow through recessions, lawsuits, and bear markets.
Why it matters — The item’s focus on durable dividends may interest JNJ watchers, though the supplied text does not identify either stock.
The 23 Wall Street analysts covering Johnson & Johnson have a median 12-month price target of $281, with estimates ranging from $190 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 23 analysts covering Johnson & Johnson, 16 rate it a Buy, 6 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Johnson & Johnson 84 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Johnson & Johnson ranks 84 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).
No one can know that. What the data says: the median 12-month target from 23 analysts implies +3.5% from the last close, and Ticker Nerd's factor model ranks Johnson & Johnson 84 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Johnson & Johnson publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for JNJ are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $190 to $320 over the next 12 months.
Johnson & Johnson returned +48.2% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular care, while its MedTech segment provides medical devices and solutions used in surgery, orthopedics, interventional procedures, and vision care.
The most recent item we track (24/7 Wall Street, 27 Oct 2026): "Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks". The item says Medtronic’s 49-year dividend-raising streak is surpassed by two medical-device rivals. It points to differences in dividend yield, valuation, and balance-sheet strength among the companies.
Johnson & Johnson is a global healthcare company that develops, manufactures, and markets a broad range of products across pharmaceuticals and medical technology. Its Innovative Medicine segment focuses on therapies in areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular care, while its MedTech segment provides medical devices and solutions used in surgery, orthopedics, interventional procedures, and vision care. The company serves hospitals, clinicians, patients, and healthcare systems in markets around the world, making it a central participant in both drug development and medical device supply chains. Johnson & Johnson is known for operating at the intersection of large-scale research, clinical innovation, and essential healthcare delivery, with products that support prevention, treatment, diagnosis, and recovery across a wide range of medical settings.
CEO Mr. Joaquin Duato · 138,200 employees · United States · https://www.jnj.com
